IgM
EstablishedIgM indicates recent infection in serology testing; monoclonal IgM is diagnostic for Waldenström macroglobulinemia.
IgM is the first antibody the body makes against a new infection, useful for confirming something is recent rather than old. A very high, single-type (monoclonal) IgM points toward a specific blood cancer called Waldenström macroglobulinemia rather than an infection.
Immunoglobulin M (IgM) is the first antibody produced in a new immune response, useful for identifying acute or recent infection before IgG antibodies fully develop.
Elevated IgM supports recent/acute infection when interpreting infectious disease serology; markedly elevated monoclonal IgM is the hallmark of Waldenström macroglobulinemia, a distinct B-cell lymphoma requiring different diagnostic criteria than IgG- or IgA-type monoclonal gammopathies.
Measured via serum immunoassay; monoclonal IgM detected on serum protein electrophoresis prompts bone marrow evaluation and MYD88 mutation testing, which is present in the large majority of Waldenström macroglobulinemia cases.
Confirmed Waldenström macroglobulinemia may be treated with BTK inhibitors, rituximab-based regimens, or other targeted therapies depending on MYD88/CXCR4 mutation status, which increasingly guides treatment selection.
MYD88 mutation testing, present in most Waldenström cases, increasingly guides treatment selection.
- General hematology reference literature on Waldenström macroglobulinemia diagnosis and MYD88 mutation testing.